MedTrace Logo

A Multicenter Assessment of ALD403 in Chronic Migraine

NCT02275117 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 665

Last updated 2020-04-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess ALD403 in the prevention of migraine headache in chronic migraineurs.

Conditions

  • Migraine Disorders

Interventions

BIOLOGICAL

ALD403

BIOLOGICAL

Placebo

Sponsors & Collaborators

  • Alder Biopharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Jeff TL Smith, MD · Alder Biopharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2016-03-31
Completion
2016-11-30

Countries

  • United States
  • Australia
  • Georgia
  • New Zealand

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02275117 on ClinicalTrials.gov